MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY
Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients. BERKELEY, US – MAINZ, Germany – February 6, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announces the opening […]
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
BERKELEY, US – MAINZ, Germany – January 11, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, re-affirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium on January 12th–13th, 2024. The companies joined forces to advance innovative colorectal cancer (CRC) […]
Mainz Biomed Provides Year-End Corporate Review 2023
European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competition ReconAAsense designed to evaluate gold standard at home colorectal cancer screening test and is on track to commence enrollment in mid-2024 Expanded international commercialization of ColoAlert® in major European markets and Israel […]
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and Crimmitschau, in Q1 2024. BERKELEY, US – MAINZ, Germany – December 19, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic […]
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
BERKELEY, US – MAINZ, Germany – DECEMBER 12, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) […]
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
Groundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82% Results Exceed those from the Company’s European ColoFuture Clinical Study of the Same Design ColoFuture and eAArly DETECT Studies Support Inclusion of a Portfolio of Novel mRNA Biomarkers in Pivotal FDA PMA Clinical Trial (ReconAAsense); Trial […]
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
BERKELEY, US – MAINZ, Germany – NOVEMBER 29, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its presentation at the 35th Annual Piper Sandler Healthcare Conference, to be delivered by Chief Executive Officer, Guido Baechler and Bill Caragol, […]
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
BERKELEY, US – MAINZ, Germany – November 20, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that Guido Baechler, Chief Executive Officer and Bill Caragol, Chief Financial Officer, will present at the 35th Annual Piper Sandler Healthcare Conference taking […]
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023 ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 80% BERKELEY, US – MAINZ, Germany – November 16, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), […]
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
BERKELEY, US – MAINZ, Germany – NOVEMBER 15, 2023 — Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced registered direct offering with several institutional investors to purchase $5.0 million of its ordinary shares […]
